@misc{humbert_m._omalizumab_2014,
	title = {Omalizumab in {Asthma}: {An} {Update} on {Recent} {Developments}},
	url = {http://www.elsevier.com/journals/the-journal-of-allergy-and-clinical-immunology-in-practice/2213-2198},
	abstract = {IgE is central to the pathophysiology of allergic asthma. Omalizumab, a humanized anti-IgE mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of IgE with its high-affinity FcepsilonRI receptors on mast cells, antigen-presenting cells, and other inflammatory cells. The clinical efficacy of omalizumab has been well documented in a number of clinical trials that involve adults, adolescents, and children with moderate-to-severe and severe allergic asthma. In these studies, omalizumab reduced exacerbations, asthma symptoms, inhaled corticosteroid and rescue medication use, and improved quality of life relative to placebo or best standard of care. Similar benefits have been reported in observational studies in "real-world" populations of patients. Results from recent pooled data from randomized clinical trials and from a large prospective cohort study provide reassurance about the long-term safety of omalizumab. Omalizumab dosing is individualized according to body weight and serum-IgE level, and recent adjustments to the dosing algorithm in Europe have enabled more patients to be eligible for treatment. Ongoing and future research is investigating the optimal duration of therapy, accurate predictors of response to treatment, and efficacy in nonatopic asthma as well as other IgE-mediated conditions. Copyright © 2014 American Academy of Allergy, Asthma \& Immunology.},
	journal = {Journal of Allergy and Clinical Immunology: In Practice},
	author = {{Humbert M.} and {Busse W.} and {Hanania N.A.} and {Lowe P.J.} and {Canvin J.} and {Erpenbeck V.J.} and {Holgate S.}},
	year = {2014},
	keywords = {*allergic asthma, *allergic asthma/dm [Disease Management], *allergic asthma/dt [Drug Therapy], *asthma, *immunoglobulin E antibody, *omalizumab, *omalizumab/ae [Adverse Drug Reaction], *omalizumab/ct [Clinical Trial], *omalizumab/dt [Drug Therapy], *omalizumab/pd [Pharmacology], *omalizumab/pe [Pharmacoeconomics], *omalizumab/sc [Subcutaneous Drug Administration], Child, Europe, adolescent, adult, algorithm, allergic asthma/dt [Drug Therapy], anaphylaxis/si [Side Effect], antigen presenting cell, arterial thromboembolism/si [Side Effect], article, beta 2 adrenergic receptor stimulating agent/dt [Drug Therapy], body weight, clinical trial (topic), cohort analysis, corticosteroid, corticosteroid/dt [Drug Therapy], corticosteroid/ih [Inhalational Drug Administration], corticosteroid/po [Oral Drug Administration], cost effectiveness analysis, disease exacerbation, drug cost, drug effect, drug efficacy, drug mechanism, drug safety, drug therapy, drug use, headache/si [Side Effect], health care quality, health care utilization, hospitalization, human, immunoglobulin E, immunoglobulin E/ec [Endogenous Compound], immunoglobulin blood level, inflammatory cell, long acting beta2 adrenoceptor agonist/dt [Drug Therapy], long term care, malignant neoplastic disease/si [Side Effect], mast cell, nose polyp/dt [Drug Therapy], observational study, pathophysiology, patient, patient monitoring, placebo, population, pregnancy outcome, quality of life, reassurance, receptor, respiratory tract inflammation, rhinopharyngitis/si [Side Effect], safety, serum, serum sickness/si [Side Effect], sinusitis/si [Side Effect], symptom, thrombocytopenia/si [Side Effect], treatment duration, treatment response, unclassified drug, upper respiratory tract infection/si [Side Effect], urticaria/si [Side Effect]}
}

{"_id":"7GkpXbz76CiLWtknH","bibbaseid":"humbertm-bussew-hananiana-lowepj-canvinj-erpenbeckvj-holgates-omalizumabinasthmaanupdateonrecentdevelopments-2014","downloads":0,"creationDate":"2017-05-12T20:20:57.466Z","title":"Omalizumab in Asthma: An Update on Recent Developments","author_short":["Humbert M.","Busse W.","Hanania N.A.","Lowe P.J.","Canvin J.","Erpenbeck V.J.","Holgate S."],"year":2014,"bibtype":"misc","biburl":"http://bibbase.org/zotero/gxu917","bibdata":{"bibtype":"misc","type":"misc","title":"Omalizumab in Asthma: An Update on Recent Developments","url":"http://www.elsevier.com/journals/the-journal-of-allergy-and-clinical-immunology-in-practice/2213-2198","abstract":"IgE is central to the pathophysiology of allergic asthma. Omalizumab, a humanized anti-IgE mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of IgE with its high-affinity FcepsilonRI receptors on mast cells, antigen-presenting cells, and other inflammatory cells. The clinical efficacy of omalizumab has been well documented in a number of clinical trials that involve adults, adolescents, and children with moderate-to-severe and severe allergic asthma. In these studies, omalizumab reduced exacerbations, asthma symptoms, inhaled corticosteroid and rescue medication use, and improved quality of life relative to placebo or best standard of care. Similar benefits have been reported in observational studies in \"real-world\" populations of patients. Results from recent pooled data from randomized clinical trials and from a large prospective cohort study provide reassurance about the long-term safety of omalizumab. Omalizumab dosing is individualized according to body weight and serum-IgE level, and recent adjustments to the dosing algorithm in Europe have enabled more patients to be eligible for treatment. Ongoing and future research is investigating the optimal duration of therapy, accurate predictors of response to treatment, and efficacy in nonatopic asthma as well as other IgE-mediated conditions. Copyright © 2014 American Academy of Allergy, Asthma & Immunology.","journal":"Journal of Allergy and Clinical Immunology: In Practice","author":[{"firstnames":[],"propositions":[],"lastnames":["Humbert M."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Busse W."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Hanania N.A."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Lowe P.J."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Canvin J."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Erpenbeck V.J."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Holgate S."],"suffixes":[]}],"year":"2014","keywords":"*allergic asthma, *allergic asthma/dm [Disease Management], *allergic asthma/dt [Drug Therapy], *asthma, *immunoglobulin E antibody, *omalizumab, *omalizumab/ae [Adverse Drug Reaction], *omalizumab/ct [Clinical Trial], *omalizumab/dt [Drug Therapy], *omalizumab/pd [Pharmacology], *omalizumab/pe [Pharmacoeconomics], *omalizumab/sc [Subcutaneous Drug Administration], Child, Europe, adolescent, adult, algorithm, allergic asthma/dt [Drug Therapy], anaphylaxis/si [Side Effect], antigen presenting cell, arterial thromboembolism/si [Side Effect], article, beta 2 adrenergic receptor stimulating agent/dt [Drug Therapy], body weight, clinical trial (topic), cohort analysis, corticosteroid, corticosteroid/dt [Drug Therapy], corticosteroid/ih [Inhalational Drug Administration], corticosteroid/po [Oral Drug Administration], cost effectiveness analysis, disease exacerbation, drug cost, drug effect, drug efficacy, drug mechanism, drug safety, drug therapy, drug use, headache/si [Side Effect], health care quality, health care utilization, hospitalization, human, immunoglobulin E, immunoglobulin E/ec [Endogenous Compound], immunoglobulin blood level, inflammatory cell, long acting beta2 adrenoceptor agonist/dt [Drug Therapy], long term care, malignant neoplastic disease/si [Side Effect], mast cell, nose polyp/dt [Drug Therapy], observational study, pathophysiology, patient, patient monitoring, placebo, population, pregnancy outcome, quality of life, reassurance, receptor, respiratory tract inflammation, rhinopharyngitis/si [Side Effect], safety, serum, serum sickness/si [Side Effect], sinusitis/si [Side Effect], symptom, thrombocytopenia/si [Side Effect], treatment duration, treatment response, unclassified drug, upper respiratory tract infection/si [Side Effect], urticaria/si [Side Effect]","bibtex":"@misc{humbert_m._omalizumab_2014,\n\ttitle = {Omalizumab in {Asthma}: {An} {Update} on {Recent} {Developments}},\n\turl = {http://www.elsevier.com/journals/the-journal-of-allergy-and-clinical-immunology-in-practice/2213-2198},\n\tabstract = {IgE is central to the pathophysiology of allergic asthma. Omalizumab, a humanized anti-IgE mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of IgE with its high-affinity FcepsilonRI receptors on mast cells, antigen-presenting cells, and other inflammatory cells. The clinical efficacy of omalizumab has been well documented in a number of clinical trials that involve adults, adolescents, and children with moderate-to-severe and severe allergic asthma. In these studies, omalizumab reduced exacerbations, asthma symptoms, inhaled corticosteroid and rescue medication use, and improved quality of life relative to placebo or best standard of care. Similar benefits have been reported in observational studies in \"real-world\" populations of patients. Results from recent pooled data from randomized clinical trials and from a large prospective cohort study provide reassurance about the long-term safety of omalizumab. Omalizumab dosing is individualized according to body weight and serum-IgE level, and recent adjustments to the dosing algorithm in Europe have enabled more patients to be eligible for treatment. Ongoing and future research is investigating the optimal duration of therapy, accurate predictors of response to treatment, and efficacy in nonatopic asthma as well as other IgE-mediated conditions. Copyright © 2014 American Academy of Allergy, Asthma \\& Immunology.},\n\tjournal = {Journal of Allergy and Clinical Immunology: In Practice},\n\tauthor = {{Humbert M.} and {Busse W.} and {Hanania N.A.} and {Lowe P.J.} and {Canvin J.} and {Erpenbeck V.J.} and {Holgate S.}},\n\tyear = {2014},\n\tkeywords = {*allergic asthma, *allergic asthma/dm [Disease Management], *allergic asthma/dt [Drug Therapy], *asthma, *immunoglobulin E antibody, *omalizumab, *omalizumab/ae [Adverse Drug Reaction], *omalizumab/ct [Clinical Trial], *omalizumab/dt [Drug Therapy], *omalizumab/pd [Pharmacology], *omalizumab/pe [Pharmacoeconomics], *omalizumab/sc [Subcutaneous Drug Administration], Child, Europe, adolescent, adult, algorithm, allergic asthma/dt [Drug Therapy], anaphylaxis/si [Side Effect], antigen presenting cell, arterial thromboembolism/si [Side Effect], article, beta 2 adrenergic receptor stimulating agent/dt [Drug Therapy], body weight, clinical trial (topic), cohort analysis, corticosteroid, corticosteroid/dt [Drug Therapy], corticosteroid/ih [Inhalational Drug Administration], corticosteroid/po [Oral Drug Administration], cost effectiveness analysis, disease exacerbation, drug cost, drug effect, drug efficacy, drug mechanism, drug safety, drug therapy, drug use, headache/si [Side Effect], health care quality, health care utilization, hospitalization, human, immunoglobulin E, immunoglobulin E/ec [Endogenous Compound], immunoglobulin blood level, inflammatory cell, long acting beta2 adrenoceptor agonist/dt [Drug Therapy], long term care, malignant neoplastic disease/si [Side Effect], mast cell, nose polyp/dt [Drug Therapy], observational study, pathophysiology, patient, patient monitoring, placebo, population, pregnancy outcome, quality of life, reassurance, receptor, respiratory tract inflammation, rhinopharyngitis/si [Side Effect], safety, serum, serum sickness/si [Side Effect], sinusitis/si [Side Effect], symptom, thrombocytopenia/si [Side Effect], treatment duration, treatment response, unclassified drug, upper respiratory tract infection/si [Side Effect], urticaria/si [Side Effect]}\n}\n\n","author_short":["Humbert M.","Busse W.","Hanania N.A.","Lowe P.J.","Canvin J.","Erpenbeck V.J.","Holgate S."],"key":"humbert_m._omalizumab_2014","id":"humbert_m._omalizumab_2014","bibbaseid":"humbertm-bussew-hananiana-lowepj-canvinj-erpenbeckvj-holgates-omalizumabinasthmaanupdateonrecentdevelopments-2014","role":"author","urls":{"Paper":"http://www.elsevier.com/journals/the-journal-of-allergy-and-clinical-immunology-in-practice/2213-2198"},"keyword":["*allergic asthma","*allergic asthma/dm [Disease Management]","*allergic asthma/dt [Drug Therapy]","*asthma","*immunoglobulin E antibody","*omalizumab","*omalizumab/ae [Adverse Drug Reaction]","*omalizumab/ct [Clinical Trial]","*omalizumab/dt [Drug Therapy]","*omalizumab/pd [Pharmacology]","*omalizumab/pe [Pharmacoeconomics]","*omalizumab/sc [Subcutaneous Drug Administration]","Child","Europe","adolescent","adult","algorithm","allergic asthma/dt [Drug Therapy]","anaphylaxis/si [Side Effect]","antigen presenting cell","arterial thromboembolism/si [Side Effect]","article","beta 2 adrenergic receptor stimulating agent/dt [Drug Therapy]","body weight","clinical trial (topic)","cohort analysis","corticosteroid","corticosteroid/dt [Drug Therapy]","corticosteroid/ih [Inhalational Drug Administration]","corticosteroid/po [Oral Drug Administration]","cost effectiveness analysis","disease exacerbation","drug cost","drug effect","drug efficacy","drug mechanism","drug safety","drug therapy","drug use","headache/si [Side Effect]","health care quality","health care utilization","hospitalization","human","immunoglobulin E","immunoglobulin E/ec [Endogenous Compound]","immunoglobulin blood level","inflammatory cell","long acting beta2 adrenoceptor agonist/dt [Drug Therapy]","long term care","malignant neoplastic disease/si [Side Effect]","mast cell","nose polyp/dt [Drug Therapy]","observational study","pathophysiology","patient","patient monitoring","placebo","population","pregnancy outcome","quality of life","reassurance","receptor","respiratory tract inflammation","rhinopharyngitis/si [Side Effect]","safety","serum","serum sickness/si [Side Effect]","sinusitis/si [Side Effect]","symptom","thrombocytopenia/si [Side Effect]","treatment duration","treatment response","unclassified drug","upper respiratory tract infection/si [Side Effect]","urticaria/si [Side Effect]"],"downloads":0,"html":""},"search_terms":["omalizumab","asthma","update","recent","developments","humbert m.","busse w.","hanania n.a.","lowe p.j.","canvin j.","erpenbeck v.j.","holgate s."],"keywords":["*allergic asthma","*allergic asthma/dm [disease management]","*allergic asthma/dt [drug therapy]","*asthma","*immunoglobulin e antibody","*omalizumab","*omalizumab/ae [adverse drug reaction]","*omalizumab/ct [clinical trial]","*omalizumab/dt [drug therapy]","*omalizumab/pd [pharmacology]","*omalizumab/pe [pharmacoeconomics]","*omalizumab/sc [subcutaneous drug administration]","child","europe","adolescent","adult","algorithm","allergic asthma/dt [drug therapy]","anaphylaxis/si [side effect]","antigen presenting cell","arterial thromboembolism/si [side effect]","article","beta 2 adrenergic receptor stimulating agent/dt [drug therapy]","body weight","clinical trial (topic)","cohort analysis","corticosteroid","corticosteroid/dt [drug therapy]","corticosteroid/ih [inhalational drug administration]","corticosteroid/po [oral drug administration]","cost effectiveness analysis","disease exacerbation","drug cost","drug effect","drug efficacy","drug mechanism","drug safety","drug therapy","drug use","headache/si [side effect]","health care quality","health care utilization","hospitalization","human","immunoglobulin e","immunoglobulin e/ec [endogenous compound]","immunoglobulin blood level","inflammatory cell","long acting beta2 adrenoceptor agonist/dt [drug therapy]","long term care","malignant neoplastic disease/si [side effect]","mast cell","nose polyp/dt [drug therapy]","observational study","pathophysiology","patient","patient monitoring","placebo","population","pregnancy outcome","quality of life","reassurance","receptor","respiratory tract inflammation","rhinopharyngitis/si [side effect]","safety","serum","serum sickness/si [side effect]","sinusitis/si [side effect]","symptom","thrombocytopenia/si [side effect]","treatment duration","treatment response","unclassified drug","upper respiratory tract infection/si [side effect]","urticaria/si [side effect]"],"authorIDs":[],"dataSources":["9LqPNaySNpNxYBFzj"]}